The lipodystrophy syndrome as a risk marker for cardiovascular disease in patients with HIV / AIDS treated with HAART | Zendy

Valdelias Xavier Pereira | Zendy; Luíz Carlos de Abreu | Zendy; Vítor Engrácia Valenti | Zendy; Rodrigo Daminello Raimundo | Zendy; Mariliza Henrique da Silva | Zendy; Fernando Rocha Oliveira | Zendy; Renata Salatini | Zendy; Adriano L. Roque | Zendy; Márcia de Toledo Blake | Zendy; E. Dias | Zendy; Celso Ferreira Filho | Zendy; Vivian Ribeiro Finotti | Zendy; Celso Ferreira | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The lipodystrophy syndrome as a risk marker for cardiovascular disease in patients with HIV / AIDS treated with HAART

Author(s) -

Valdelias Xavier Pereira,

Luíz Carlos de Abreu,

Vítor Engrácia Valenti,

Rodrigo Daminello Raimundo,

Mariliza Henrique da Silva,

Fernando Rocha Oliveira,

Renata Salatini,

Adriano L. Roque,

Márcia de Toledo Blake,

E. Dias,

Celso Ferreira Filho,

Vivian Ribeiro Finotti,

Celso Ferreira

Publication year - 2015

Publication title -

international archives of medicine

Language(s) - English

Resource type - Journals

ISSN - 1755-7682

DOI - 10.3823/1677

Subject(s) - lipodystrophy , medicine , lipoatrophy , metabolic syndrome , disease , hyperlipidemia , diabetes mellitus , human immunodeficiency virus (hiv) , immunology , endocrinology , antiretroviral therapy , viral load

The classic risk factors for cardiovascular disease in healthy individuals are well known, however, it lacks in the literature the mechanisms that predicts cardiovascular disease in the population living with HIV-AIDS treated with HAART and presenting syndrome lipodystrophy. We aimed to investigate the risk of cardiovascular disease in HIV-AIDS patients treated with HAART and lipodystrophy syndrome. Methods: A search was performed in Medline, SciELO, Lilacs and Cochrane using the intersection between the keywords: "cardiovascular disease", "HIV", "AIDS", "HAART" and "lipodystrophy syndrome". Results: The selected studies demonstrated that metabolic disorders such as hyperlipidemia, central adipose hypertrophy and peripheral lipoatrophy, besides the metabolic syndrome and lipodystrophy are maker clear risks of developing cardiovascular disease in these individuals. Conclusion: The metabolic alterations in HIV-AIDS treated with HAART and presenting lipodystrophy syndrome may potentiate the development of cardiovascular diseases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research